Folate, vitamin B12, and homocysteine in major depressive disorder

Maurizio Fava, Joseph S. Borus, Jonathan E. Alpert, Andrew A. Nierenberg, Jerrold F. Rosenbaum, Teodoro Bottiglieri

Research output: Contribution to journalArticle

256 Citations (Scopus)

Abstract

Objective: The authors examined the relationships between levels of three metabolites (folate, vitamin B12, and homocysteine) and both depressive subtype and response to fluoxetine treatment in depressed patients. Method: Fluoxetine. 20 mg/day for 8 weeks, was given to 213 outpatients with major depressive disorder. At baseline, depressive subtypes were assessed, and a blood sample was collected from each patient. Serum metabolite levels were assayed. Response to treatment was determined by percentage change in score on the 17-item Hamilton Depression Rating Scale. Results: Subjects with low folate levels were more likely to have melancholic depression and were significantly less likely to respond to fluoxetine. Homocysteine and B12 levels were not associated with depressive subtype or treatment response. Conclusions: Overall, the results are consistent with findings linking low folate levels to poorer response to antidepressant treatment. Folate levels might be considered in the evaluation of depressed patients who do not respond to antidepressant treatment.

Original languageEnglish (US)
Pages (from-to)426-428
Number of pages3
JournalAmerican Journal of Psychiatry
Volume154
Issue number3
StatePublished - 1997
Externally publishedYes

Fingerprint

Major Depressive Disorder
Homocysteine
Vitamin B 12
Folic Acid
Fluoxetine
Antidepressive Agents
Depression
Therapeutics
Outpatients
Serum

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Fava, M., Borus, J. S., Alpert, J. E., Nierenberg, A. A., Rosenbaum, J. F., & Bottiglieri, T. (1997). Folate, vitamin B12, and homocysteine in major depressive disorder. American Journal of Psychiatry, 154(3), 426-428.

Folate, vitamin B12, and homocysteine in major depressive disorder. / Fava, Maurizio; Borus, Joseph S.; Alpert, Jonathan E.; Nierenberg, Andrew A.; Rosenbaum, Jerrold F.; Bottiglieri, Teodoro.

In: American Journal of Psychiatry, Vol. 154, No. 3, 1997, p. 426-428.

Research output: Contribution to journalArticle

Fava, M, Borus, JS, Alpert, JE, Nierenberg, AA, Rosenbaum, JF & Bottiglieri, T 1997, 'Folate, vitamin B12, and homocysteine in major depressive disorder', American Journal of Psychiatry, vol. 154, no. 3, pp. 426-428.
Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T. Folate, vitamin B12, and homocysteine in major depressive disorder. American Journal of Psychiatry. 1997;154(3):426-428.
Fava, Maurizio ; Borus, Joseph S. ; Alpert, Jonathan E. ; Nierenberg, Andrew A. ; Rosenbaum, Jerrold F. ; Bottiglieri, Teodoro. / Folate, vitamin B12, and homocysteine in major depressive disorder. In: American Journal of Psychiatry. 1997 ; Vol. 154, No. 3. pp. 426-428.
@article{3ba0140705f64aedb7edb88bc7df9522,
title = "Folate, vitamin B12, and homocysteine in major depressive disorder",
abstract = "Objective: The authors examined the relationships between levels of three metabolites (folate, vitamin B12, and homocysteine) and both depressive subtype and response to fluoxetine treatment in depressed patients. Method: Fluoxetine. 20 mg/day for 8 weeks, was given to 213 outpatients with major depressive disorder. At baseline, depressive subtypes were assessed, and a blood sample was collected from each patient. Serum metabolite levels were assayed. Response to treatment was determined by percentage change in score on the 17-item Hamilton Depression Rating Scale. Results: Subjects with low folate levels were more likely to have melancholic depression and were significantly less likely to respond to fluoxetine. Homocysteine and B12 levels were not associated with depressive subtype or treatment response. Conclusions: Overall, the results are consistent with findings linking low folate levels to poorer response to antidepressant treatment. Folate levels might be considered in the evaluation of depressed patients who do not respond to antidepressant treatment.",
author = "Maurizio Fava and Borus, {Joseph S.} and Alpert, {Jonathan E.} and Nierenberg, {Andrew A.} and Rosenbaum, {Jerrold F.} and Teodoro Bottiglieri",
year = "1997",
language = "English (US)",
volume = "154",
pages = "426--428",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "3",

}

TY - JOUR

T1 - Folate, vitamin B12, and homocysteine in major depressive disorder

AU - Fava, Maurizio

AU - Borus, Joseph S.

AU - Alpert, Jonathan E.

AU - Nierenberg, Andrew A.

AU - Rosenbaum, Jerrold F.

AU - Bottiglieri, Teodoro

PY - 1997

Y1 - 1997

N2 - Objective: The authors examined the relationships between levels of three metabolites (folate, vitamin B12, and homocysteine) and both depressive subtype and response to fluoxetine treatment in depressed patients. Method: Fluoxetine. 20 mg/day for 8 weeks, was given to 213 outpatients with major depressive disorder. At baseline, depressive subtypes were assessed, and a blood sample was collected from each patient. Serum metabolite levels were assayed. Response to treatment was determined by percentage change in score on the 17-item Hamilton Depression Rating Scale. Results: Subjects with low folate levels were more likely to have melancholic depression and were significantly less likely to respond to fluoxetine. Homocysteine and B12 levels were not associated with depressive subtype or treatment response. Conclusions: Overall, the results are consistent with findings linking low folate levels to poorer response to antidepressant treatment. Folate levels might be considered in the evaluation of depressed patients who do not respond to antidepressant treatment.

AB - Objective: The authors examined the relationships between levels of three metabolites (folate, vitamin B12, and homocysteine) and both depressive subtype and response to fluoxetine treatment in depressed patients. Method: Fluoxetine. 20 mg/day for 8 weeks, was given to 213 outpatients with major depressive disorder. At baseline, depressive subtypes were assessed, and a blood sample was collected from each patient. Serum metabolite levels were assayed. Response to treatment was determined by percentage change in score on the 17-item Hamilton Depression Rating Scale. Results: Subjects with low folate levels were more likely to have melancholic depression and were significantly less likely to respond to fluoxetine. Homocysteine and B12 levels were not associated with depressive subtype or treatment response. Conclusions: Overall, the results are consistent with findings linking low folate levels to poorer response to antidepressant treatment. Folate levels might be considered in the evaluation of depressed patients who do not respond to antidepressant treatment.

UR - http://www.scopus.com/inward/record.url?scp=0030614878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030614878&partnerID=8YFLogxK

M3 - Article

C2 - 9054796

AN - SCOPUS:0030614878

VL - 154

SP - 426

EP - 428

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 3

ER -